Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Table 1

Lenalidomide monotherapy trials.

Author	Year	Phase	Histology	𝑛	Age (range)	Previous CT (range)	Rituximab refractory (%)	Schedule	ORR (%)	CR/CRu (%)	Median DR (months)
Wiernik et al. [10]	2008	II	Indolent NHL (10.2%)	49	65 (23–86)	4 (NR)	58	Lenalidomide 25 mg 21q28 days	60	20	6.2
			MCL (30.6%)						53	13.3
Witzig et al. [11]	2009	II	Indolent NHL (100%)	43	63 (42–89)	3 (1–17)	67	Lenalidomide 25 mg 21q28 days	23	7	Not reached 16.5
Reeder et al. [12]	2009	II	MCL (100%)	54	69 (33–82)	3 (1–8)	NR	Lenalidomide 25 mg 21q28 days	43	17	NR
Habermann et al. [13]	2009	II	MCL (100%)	15	66 (45–84)	4 (2–7)	58	Lenalidomide 25 mg 21q28 days	53	20	Not reached 13.7
Witzig et al. [14]	2011	II	MCL (26.3%)	217	66 (21–87)	3 (1–13)	53.9	Lenalidomide; 25 mg 21q28 days	42	21	Not reached 8.9

ORR: overall response-rate; CT: chemotherapy; CR/Cru: complete response/complete response unconfirmed; DR: duration of response; NR: not reported.